๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Adlai Nortye Group Ltd. (ANL)
NASDAQ: ANL ยท Real-Time Price ยท USD
8.55
-0.51 (-5.63%)
At close: Nov 20, 2026, 4:00 PM EST
8.52
-0.04 (-0.41%)
After-hours: Nov 20, 2026, 4:15 PM EST

Adlai Nortye Group Earnings Call Transcripts

Fiscal Year 2026

  • The H1 2027 AN9025 readout is expected to include at least 50 efficacious-dose patients, predominantly with PDAC; differentiation will hinge on efficacy, tolerability and combination potential. AN4035 data are expected in H2 2027, with ~$232 million in H1 2026 cash projected to fund both catalysts and operations through 2028.

  • The event highlighted progress on two lead oncology assets: AN9025, a potent oral pan-RAS(ON) inhibitor in phase I trials with both daily and weekly dosing, and AN4035, a first-in-class ADC targeting CEACAM5. Key clinical data are expected in 2027, supported by a strong cash position.

  • Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.